US › Healthcare

Bright Minds Biosciences Inc (DRUG)

US · Healthcare · Biotechnology

$51.30-5.37%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.5M

EPS

$-0.17

EPS estimate

$-1.39

EPS came in at -0.17 against a street estimate of -1.39 — a beat of 87.8%.

Key statistics

Market cap

$534.7M

Forward P/E

0.0

P/B

2.60

Book value

$21.95

EPS (TTM)

$-2.05

52-week high

$123.75

52-week low

$47.23

50-day MA

$65.57

200-day MA

$75.20

Beta

0.23

Analyst view

Analysts rate Bright Minds Biosciences Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $152.88.

Shareholding

Insiders

11.94%

Institutions

94.95%

Largest institutional holders

Fund	Stake
Jupiter Topco LLC	13.68%
HHG PLC	13.02%
Cormorant Asset Management, LLC	9.12%
BlackRock Inc	6.96%
Vivo Capital, LLC	5.65%
Vestal Point Capital LP	5.53%
BRAIDWELL LP	4.90%
Driehaus Capital Management LLC	4.39%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bright Minds Biosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.